Want to see JP:3353 full AI Analyst Report?
Top Page
Medical Ikkou Group Co., Ltd.
(3353)
Select Model
Select Model
Rating:72Outperform
Price Target:
¥3,171.00
▲(8.23% Upside)
Action:Upgraded
Date:08/04/26
The score is driven by attractive valuation (low P/E and strong dividend yield) and supportive technical momentum (price above major moving averages with positive MACD). Offsetting these positives, financial performance is capped by weak and volatile cash-flow conversion relative to reported earnings despite improving revenue and reduced leverage.
Positive Factors
Reimbursement-backed revenue
The company’s core revenue is tied to dispensing pharmacies and reimbursed dispensing fees under Japan’s healthcare insurance. This creates a structurally recurring cash flow base linked to prescription volumes and fee schedules, supporting predictable long-term revenue streams.
Negative Factors
Weak cash conversion
Operating cash flow well below reported earnings and volatile free cash flow undermine earnings quality and limit internal funding. This constrains capacity to reliably fund capex, store rollouts, dividends, or repay debt, raising execution risk on strategic initiatives over the medium term.
Read all positive and negative factors
Positive Factors
Negative Factors
Reimbursement-backed revenue
The company’s core revenue is tied to dispensing pharmacies and reimbursed dispensing fees under Japan’s healthcare insurance. This creates a structurally recurring cash flow base linked to prescription volumes and fee schedules, supporting predictable long-term revenue streams.
Read all positive factors
Medical Ikkou Group Co., Ltd. (3353) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
¥9.82B
Dividend Yield4.22%
Average Volume (3M)5.09K
Price to Earnings (P/E)7.3
Beta (1Y)0.46
Revenue Growth10.11%
EPS Growth28.97%
CountryJP
Employees1,608
SectorIndustrials
Sector Strength72
IndustryConglomerates
Share Statistics
EPS (TTM)338.74
Shares Outstanding3,770,000
10 Day Avg. Volume10,430
30 Day Avg. Volume5,086
Financial Highlights & Ratios
PEG Ratio0.73
Price to Book (P/B)0.73
Price to Sales (P/S)0.21
P/FCF Ratio52.19
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Medical Ikkou Group Co., Ltd. Business Overview & Revenue Model
Company Description
Medical Ikkou Group Co., Ltd. (3353) is a Japan-based healthcare company that operates primarily in the pharmaceutical and medical services domain. The group’s core activities include the operation of dispensing (prescription) pharmacies and relat...
How the Company Makes Money
Medical Ikkou Group generates revenue mainly through (1) dispensing pharmacy operations, where it fills outpatient prescriptions issued by clinics and hospitals and receives payments comprised of reimbursed dispensing fees and medicine costs under...
Medical Ikkou Group Co., Ltd. Financial Statement Overview
Summary
Income Statement
74
Positive
Balance Sheet
70
Positive
Cash Flow
46
Neutral
| Breakdown | Feb 2026 | Feb 2025 | Feb 2024 | Feb 2023 | Feb 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 54.98B | 48.39B | 39.90B | 33.90B | 33.60B |
| Gross Profit | 6.36B | 5.61B | 4.38B | 2.97B | 3.37B |
| EBITDA | 2.63B | 2.46B | 2.34B | 1.78B | 2.15B |
| Net Income | 1.28B | 1.13B | 1.04B | 759.60M | 852.33M |
Balance Sheet | |||||
| Total Assets | 37.52B | 34.23B | 31.66B | 27.51B | 29.09B |
| Cash, Cash Equivalents and Short-Term Investments | 6.12B | 6.77B | 7.70B | 6.44B | 7.99B |
| Total Debt | 10.36B | 10.04B | 9.60B | 9.15B | 11.35B |
| Total Liabilities | 21.24B | 19.52B | 17.82B | 14.90B | 17.17B |
| Stockholders Equity | 15.63B | 14.10B | 13.24B | 12.05B | 11.38B |
Cash Flow | |||||
| Free Cash Flow | 219.98M | 201.34M | 3.97B | 995.40M | 812.29M |
| Operating Cash Flow | 1.21B | 1.20B | 4.28B | 1.31B | 1.14B |
| Investing Cash Flow | -1.81B | -1.13B | -3.22B | -477.52M | 539.48M |
| Financing Cash Flow | -283.62M | -1.03B | 277.76M | -2.37B | -690.26M |
Medical Ikkou Group Co., Ltd. Peers Comparison
UnderperformOutperform
Sector (63)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
80 Outperform | ¥7.09B | 5.04 | ― | 3.35% | 6.84% | 9.89% | |
72 Outperform | ¥9.82B | 7.26 | ― | 3.51% | 10.11% | 28.97% | |
71 Outperform | ¥14.08B | 5.78 | ― | 4.00% | 12.00% | ― | |
70 Outperform | ¥29.19B | 12.54 | ― | 3.93% | 7.99% | 11.03% | |
70 Outperform | ¥18.63B | 17.70 | ― | 2.71% | -0.35% | 66.77% | |
63 Neutral | $10.79B | 15.43 | 7.44% | 2.01% | 2.89% | -14.66% | |
47 Neutral | ¥11.77B | 31.29 | ― | 0.72% | ― | ― |
* Industrials Sector Average
JP:3353
Medical Ikkou Group Co., Ltd.
2,865.00
-243.31
-7.83%
JP:2462
LIKE, Inc.
1,491.00
94.15
6.74%
JP:6838
Tamagawa Holdings Co., Ltd.
1,516.00
734.12
93.89%
JP:7119
halmek holdings Co.,Ltd.
1,700.00
616.40
56.88%
JP:7509
I. A Group Corporation
4,855.00
1,291.77
36.25%
JP:9248
People, Dreams & Technologies Group Co., Ltd.
1,565.00
-213.61
-12.01%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.